当前位置: X-MOL 学术Curr. Pharm. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Beta-glucans is a Potential Inhibitor of Ovarian Cancer: Based on Molecular and Biological Aspects.
Current Pharmaceutical Biotechnology ( IF 2.8 ) Pub Date : 2022-01-01 , DOI: 10.2174/1389201022666210810090728
Fatemeh Sadoughi 1 , Zatollah Asemi 1 , Jamal Hallajzadeh 2 , Mohammad Ali Mansournia 3 , Bahman Yousefi 4, 5
Affiliation  

Ovarian cancer is a lethal type of cancer which is initiated to the ovaries and affects 1 out of every 75 women. Due to the high number of deaths (almost 152,000) related to this cancer, it seems that novel efficient therapeutic methods are required in this field. Beta-glucans are a type of glucose linear polymers which have been proven to have a lot of advantageous activities. Recently, investigations have declared that these polysaccharides have the potential to be used as anti-cancer drugs. These agents are able to affect several mechanisms such as inflammation and apoptosis, and that is how cancers are prone to be affected by them. In this review, we attempt to investigate the role of beta-glucans on ovarian cancer. We hope that this paper would give some novel insights into the field of ovarian cancer treatment.

中文翻译:

β-葡聚糖是卵巢癌的潜在抑制剂:基于分子和生物学方面。

卵巢癌是一种致命类型的癌症,它起源于卵巢,每 75 名女性中就有 1 人受到影响。由于与这种癌症相关的大量死亡(近 152,000 人),似乎该领域需要新的有效治疗方法。β-葡聚糖是一种葡萄糖线性聚合物,已被证明具有许多有利的活性。最近,研究表明这些多糖具有用作抗癌药物的潜力。这些药物能够影响炎症和细胞凋亡等多种机制,这就是癌症容易受到它们影响的原因。在这篇综述中,我们试图研究 β-葡聚糖在卵巢癌中的作用。我们希望这篇论文能为卵巢癌治疗领域提供一些新的见解。
更新日期:2021-08-09
down
wechat
bug